| HOME >> BIOLOGY >> TECHNOLOGY |
MONTVALE, N.J., Jan. 17 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (Amex: SYI) today announced the signing of an agreement with privately- held Novel Therapeutic Technologies, Inc. to provide Synvista with formulation work for a topical cream formulation of ALT-2074 for the treatment of psoriasis. ALT-2074 is one of the Company's lead compounds under development for use in cardiovascular disease.
"We believe that ALT-2074 is a logical choice for a potential therapy in mild-to-moderate plaque psoriasis. TNF-alpha is an established target for drug development in psoriasis and other autoimmune diseases. The effectiveness of approved TNF antagonists may relate to their demonstrated ability to inhibit the induction of cell adhesion molecules and consequent migration of pro-inflammatory cells into inflamed tissue," said Noah Berkowitz, M.D., Ph.D., President and Chief Executive Officer of Synvista Therapeutics. "ALT-2074 can block TNF-alpha activated expression of cell adhesion molecules, I-CAM and V-CAM, which may be essential for cellular migration. As such, we believe that a topical formulation of ALT-2074 may be a promising therapy for mild-to-moderate plaque psoriasis, without the side effects associated with systemic treatment using anti-TNF biologics."
"We have identified sites in Israel to perform a planned Phase 2
clinical trial for plaque psoriasis beginning mid-2008, pending approval
from the Ministry of Health in Israel," added Dr. Berkowitz. "The Ministry
of Health is already familiar with ALT-2074 since it approved its use in
our ongoing Study 203. Based on our current timeline, assuming timely
receipt of regulatory approval, we hope to announce study results in the
fourth quarter of 2008. We expect this ps
'/>"/>
| SOURCE Synvista Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved |